{
    "clinical_study": {
        "@rank": "154596", 
        "arm_group": [
            {
                "arm_group_label": "Fingolimod 0.5mg/daily", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients will receive placebo from Weeks 0-18, and will then change over to fingolimod 0.5/mg from Weeks 18-48"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the efficacy and safety of fingolimod 0.5mg versus placebo in patients with\n      suspected acute demyelinating optic neuritis (ADON) receiving standard steroid treatment"
        }, 
        "brief_title": "Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON)", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": "Acute Demylelinating Optic Neuritis", 
        "condition_browse": {
            "mesh_term": [
                "Neuritis", 
                "Optic Neuritis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical signs and symptoms of ADON in one eye (loss of vision, pain on movement,\n             impairment of color vision)\n\n          -  First episode of ADON\n\n          -  Able to undergo treatment with IV steroids\n\n        Exclusion Criteria:\n\n          -  History of any unexplained eye or neurological symptoms lasting longer than 48 hours\n\n          -  Optic neuritis in both eyes\n\n          -  Concomitant condition in either eye, other than optic neuritis\n\n          -  History of heart condition/disease\n\n          -  Patients with uncontrolled diabetes mellitus\n\n          -  Patients with liver conditions/disease\n\n          -  Inability to undergo MRI\n\n          -  Pregnant or nursing women\n\n          -  Women of childbearing potential who are not using highly effective method of birth\n             control\n\n               -  Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "2", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01757691", 
            "org_study_id": "CFTY720D2402", 
            "secondary_id": "2012-002968-27"
        }, 
        "intervention": [
            {
                "arm_group_label": "Fingolimod 0.5mg/daily", 
                "intervention_name": "Fingolimod 0.5mg/daily", 
                "intervention_type": "Drug", 
                "other_name": "FTY, Gilenya"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Fingolimod"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Acute demyelinating optic neuritis", 
            "Optic neuritis"
        ], 
        "lastchanged_date": "June 4, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33713"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Majadanonda", 
                        "country": "Spain", 
                        "state": "Madrid", 
                        "zip": "28220"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "Germany", 
                "Italy", 
                "Portugal", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A 48-week, Double-blind, Randomized, Multi-center, Parallel-group Study Comparing Structural Changes in the Retina and Evolution of Visual Function After Immediate Versus Delayed Treatment With Fingolimod in Patients With Acute Demyelinating Optic Neuritis", 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Primary endpoint is the difference between the OCT determined retinal nerve fiber layer thickness (RNFLT) of the affected eye at the week 18 post-baseline visit and the RNFLT of the fellow eye at baseline", 
            "measure": "Mean retinal nerve fiber layer (RNFL) thinning in patients treated with fingolimod 0.5mg/day, relative to patients treated with placebo", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Week 18"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01757691"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The impact [on visual acuity], of immediate treatment with fingolimod 0.5mg/daily (48 weeks of continuous treatment) will be compared with that of delayed treatment with fingolimod 0.5mg/daily (18 weeks of placebo then 30 weeks of fingolimod), through testing with low contrast Sloan letter charts at 1.25, and 2.5% contrast levels", 
                "measure": "Low contrast visual acuity", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 48"
            }, 
            {
                "description": "The impact [on vision based quality of life], of immediate treatment with fingolimod 0.5mg/daily (48 weeks of continuous treatment) will be compared with that of delayed treatment with fingolimod 0.5mg/daily (18 weeks of placebo then 30 weeks of fingolimod), through administration of the NEI-VFQ-25 Form", 
                "measure": "Vision based quality of life (QoL)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 18, Week 48"
            }, 
            {
                "description": "The impact [on conversion to either 2005 or 2010 McDonald MS or to CDMS], of immediate treatment with fingolimod 0.5mg/daily (48 weeks of continuous treatment) will be compared with that of delayed treatment with fingolimod 0.5mg/daily (18 weeks of placebo then 30 weeks of fingolimod), through MRI testing and MS relapse assessment", 
                "measure": "Conversion to either 2005 or 2010 McDonald MS or to CDMS", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 18, Week 48"
            }, 
            {
                "description": "Safety and tolerability of fingolimod in patients with ADON will be assessed at each study visit through: physical exam, vital signs, blood sampling, urinalysis, pregnancy testing, ECG, detailed neurological exam. including EDSS. First dose monitoring will be conducted for all patients at baseline, Week 18 and re-starts after dosage interruptions, per the Protocol.", 
                "measure": "Safety and tolerability of fingolimod in patients with ADON", 
                "safety_issue": "Yes", 
                "time_frame": "Weeks 0, 4, 8, 12, 18, 24, 36, 48, 60"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}